Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

PHASE2CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 2003

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

BIOLOGICAL

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

Trial Locations (17)

10032

HIV Prevention & Treatment CRS, New York

10456

NY Blood Ctr./Bronx CRS, The Bronx

14642

Univ. of Rochester HVTN CRS, Rochester

21201

Project Brave HIV Vaccine CRS, Baltimore

21205

Johns Hopkins Bloomberg School of Public Health, Ctr. for Immunization Research, Project SAVE-DC, Baltimore

22003

Infectious Diseases Physicians, Inc., Annandale

35294

Alabama Vaccine CRS, Birmingham

37232

Vanderbilt Vaccine CRS, Nashville

63110

Saint Louis Univ. School of Medicine, HVTU, St Louis

94102

San Francisco Dept. of Public Health, San Francisco Gen. Hosp., San Francisco

98104

FHCRC/UW Vaccine CRS, Seattle

Unknown

San Francisco Vaccine and Prevention CRS, San Francisco

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore, Baltimore

NY Blood Ctr./Union Square CRS, New York

02115

Brigham and Women's Hosp. CRS, Boston

02215

Fenway Community Health Clinical Research Site (FCHCRS), Boston

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH